Studies in the fibrosarcoma model have shown that these effects can be inhibited by an anti-CD8 depleting antibody, suggesting that 5a-HSA promotes an anti-cancer immune response mediated by CD8 T cells. Here, CD8A is linked to fibrosarcoma.